International Prognostic Scoring System, Revised International Prognostic Scoring System, and Molecular International Prognostic Scoring System Had No Identical Prognostic Power Depending on Treatment in Myelodysplastic Syndromes
The IPSS-M effectively reclassified 41.9% of patients, upstaging 20.2% and downstaging 21.7%. However, our analysis found that none of the prognostic scores effectively predicted outcomes for ESA-treated patients. Further studies are needed to assess whether the predictive value of these scoring systems is influenced by the specific treatment modalities used.
Authors
- Michael Loschi
- Rinzine Sammut (ORCID: https://orcid.org/0000-0003-3015-0846)
- T. Cluzeau
- Sami Benachour
- Neila De Pooter
- Ghada Abichou
- Bochra Sedaki
- Joy Mouanes-Abelin
- Corinne Ferrero-Vacher
- Berengere Dadone-Montaudie
- Caroline Fileni
Institutions
- Inserm (FR)
- Université Côte d'Azur (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Méditerranéen de Médecine Moléculaire (FR)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2026-01-23
- DOI
- https://doi.org/10.1159/000549858
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00